Cognitive enhancers for anxiety disorders.
Cognitive-behavioral therapy is an effective intervention for anxiety disorders. However, a significant number of people do not respond or only show partial response even after an adequate course of the treatment. Recent research has shown that the efficacy of the intervention can be improved by the use of cognitive enhancers that augment the core learning processes of cognitive-behavior therapy. This manuscript provides a review of the current state of cognitive enhancers for the treatment of anxiety disorders.
Department of Psychology, Boston University, 648 Beacon Street, 6th Floor, Boston, MA 02215-2002, USA. shofmann@bu.edu
Stefan G
SG
Hofmann
Jasper A J
JA
Smits
Anu
A
Asnaani
Cassidy A
CA
Gutner
Michael W
MW
Otto
D000818:Animals; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D002110:Caffeine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D003523:Cycloserine / Q000008:administration & dosage / Q000627:therapeutic use; D005108:Extinction, Psychological / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007858:Learning / Q000187:drug effects / Q000502:physiology; D000077408:Modafinil; D018377:Neurotransmitter Agents / Q000627:therapeutic use; D018697:Nootropic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D057170:Translational Research, Biomedical; D015016:Yohimbine / Q000627:therapeutic use
D001559:Benzhydryl Compounds; D018377:Neurotransmitter Agents; D018697:Nootropic Agents; D015016:Yohimbine; D002110:Caffeine; D003523:Cycloserine; D000077408:Modafinil